Screening for chronic Q-fever is only cost-effective for specific groups RIVM has investigated for which groups screening for chronic Q-fever might be cost-effective.
Pneumococcal disease in the elderly The Health Council of the Netherlands is preparing an advice on pneumococcal vaccination for the elderly on request of the Ministry of Health, Welfare and Sport.
Statement on health care spending Down syndrome Recently a tweet containing a video from a Dutch tv-show about Down syndrome caused a lot of turmoil on Twitter.
Temporary dermal fillers prove harmless RIVM has conducted a market surveillance study of 26 so-called non-permanent fillers. All 26 products proved to be harmless.
Slight increase of the number of tuberculosis patients in 2016 For the second consecutive year, the number of tuberculosis (TB) patients in the Netherlands increased.
Promising biobased alternatives to controversial polar aprotic solvents There are a number of promising biobased alternatives to controversial polar aprotic solvents, as revealed in a report from Wageningen Food & Biobased Research commissioned by RIVM .
Proposal to calculate combined effects of chemicals in the environment at EU level Current legislation for chemicals insufficiently covers the combined effects of substances on humans and the environment.
Mental care still the most expensive of all In 2011, 19.6 billion euros was spent on the treatment of mental disorders. This amounted to 22% of the total expenditure on health and welfare during that year.
Risks of eHealth technology RIVM and Nictiz have made an overview of the risks that eHealth applications may entail and how these risks can be controlled.
Key organisations unite to improve benefit and risk assessments of vaccines Leading organisations have joined forces to launch a unique project that will pave the way for a pan-European framework for rapidly assessing and communicating the benefits and risks of vaccines.